|
시장보고서
상품코드
2102427
유전성 망막 질환 시장 규모, 점유율, 성장 분석 : 질환 유형별, 요법 유형별, 투여 경로별, 최종사용자별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)Inherited Retinal Disease Market Size, Share, and Growth Analysis, By Disease Type, By Therapy Type, By Route of Administration, By End User, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의 유전성 망막 질환 시장 규모는 2024년에 26억 7,000만 달러로 평가되었으며, 2025년 30억 달러에서 2033년까지 271억 8,000만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 12.5%로 성장할 것으로 전망됩니다.
세계 유전성 망막 질환(IRD) 시장은 색소성 망막염, 라버 선천성 실명증, 슈타르가르트병 등의 질환에 대한 진단, 치료 및 지원 서비스를 포함하며, 이러한 질환으로 인한 심각한 시력 저하로 인해 근본적인 해결책이 절실히 요구되고 있습니다. 유전자 치환 및 유전자 편집 기술의 최근 발전으로 인해 IRD는 치료 가능한 질환으로 변모했으며, 이는 생명공학 혁신에 대한 투자자들의 관심을 높이고 있습니다. 임상시험의 성공, 특히 시력 회복을 입증한 사례는 상용화 노력을 뒷받침하는 규제 및 보험 환급 체계 개선의 길을 열었습니다. 또한, 유전자 치료에 대한 보험 급여 정책의 확대와 보험 지원 확충은 이 분야를 견인하는 중요한 동향이 되고 있습니다. 바이오의약품 기업 간의 제휴를 통해 임상시험 피험자 등록이 가속화되고 환자의 접근성이 확대됨에 따라, 시장 규모는 50억 달러에 달할 것으로 예측됩니다.
세계 유전성 망막 질환 시장의 성장요인
세계 유전성 망막 질환 시장은 유전성 망막 질환과 관련된 유전자 변이를 표적으로 삼아 교정할 수 있게 해주는 유전자 편집 기술의 발전에 크게 힘입고 있습니다. 이러한 혁신적인 기법은 근본적인 유전적 원인이 아닌 주로 증상 완화에 초점을 맞추었던 기존의 치료 접근법을 뛰어넘고 있습니다. 이러한 최첨단 치료법에 대한 관심과 투자가 증가함에 따라 임상 현장에서의 개발 및 검증 속도가 가속화되고 있습니다. 또한, 유전공학 기술의 발전으로 인해 이러한 치료법의 접근성과 신뢰성이 향상되어 임상의들의 신뢰도도 높아지고 있습니다. 그 결과, 이러한 진보는 더 효과적인 임상 성과로 이어지며, 환자들의 치료 선택의 폭을 넓히고 있습니다.
세계 유전성 망막 질환 시장의 제약요인
세계 유전성 망막 질환 시장은 주로 유전자 치료 및 세포 치료에 수반되는 고비용으로 인해 큰 제약에 직면해 있습니다. 이러한 경제적 부담은 특히 제한된 자원으로 운영되는 의료 시스템에 있어 과제가 되고 있으며, 이러한 첨단 치료에 대한 접근성 확보에 어려움을 겪고 있습니다. 보상 모델은 상황을 더욱 복잡하게 만들고 지연을 초래하여, 의료 제공자가 종합적인 보험 적용을 제공하는 것을 방해하며, 환자가 본인 부담 비용을 감당할 수밖에 없는 상황을 만들어내고 있습니다. 많은 환자가 치료를 기다리고 있는 상황에서, 이러한 지연은 경제적 진전을 저해하고 시장 침투를 제한하고 있습니다. 게다가 비용 대비 효과 연구에 광범위하고 장기적인 데이터가 필요하다는 점이 가격 협상을 어렵게 만드는 한편, 생명공학 분야의 자금 부족으로 인해 실용 가능한 치료 후보의 수가 감소하고 있어 예측 불가능한 시장 역학을 초래하고 있습니다.
세계 유전성 망막 질환 시장 동향
세계 유전성 망막 질환 시장에서는 유전자 치료 파이프라인의 확장에 힘입어 혁신적인 시장 동향이 나타나고 있습니다. 벡터 설계의 혁신적인 진보는 물론, 전달 메커니즘 및 안전성 프로토콜의 강화로 인해, 그동안 치료가 충분히 이루어지지 않았던 광범위한 유전성 망막 질환에 대한 치료법 개발이 가능해지고 있습니다. 연구 기관 간의 협력 강화와 규제 환경 개선으로 인해, 전임상 연구에서 임상시험으로의 전환이 원활해지고 있습니다. 이러한 가속화는 투자자들의 큰 관심을 끌고 전략적 파트너십을 촉진하며, 치료 선택의 폭을 더욱 넓히고 시장을 발전시키며, 희귀 망막 질환에 효과적으로 대처할 수 있는 희망을 안겨주고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 유전성 망막 질환 시장 규모 : 질환 유형별
세계의 유전성 망막 질환 시장 규모 : 요법 유형별
세계의 유전성 망막 질환 시장 규모 : 투여 경로별
세계의 유전성 망막 질환 시장 규모 : 최종사용자별
세계의 유전성 망막 질환 시장 규모 : 유통 채널별
세계의 유전성 망막 질환 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSMGlobal Inherited Retinal Disease Market size was valued at USD 2.67 Billion in 2024 and is poised to grow from USD 3.0 Billion in 2025 to USD 27.18 Billion by 2033, growing at a CAGR of 12.5% during the forecast period (2026-2033).
The global inherited retinal disease (IRD) market encompasses diagnostics, therapeutics, and support services for conditions like retinitis pigmentosa, Leber congenital amaurosis, and Stargardt disease, highlighting the pressing need for curative solutions due to the significant vision loss these disorders cause. Recent advancements in gene-replacement and editing technologies have transformed IRDs into viable targets for treatment, fostering investor interest in biotech innovations. Successful trials, particularly those demonstrating vision restoration, have paved the way for improved regulatory and reimbursement frameworks that enhance commercialization efforts. Additionally, expanding reimbursement policies and insurance support for gene therapies are crucial trends propelling the sector forward. Collaborative biopharmaceutical partnerships have expedited clinical trial enrollment and broadened patient access, driving market growth toward projected revenues of $5 billion.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Inherited Retinal Disease market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Inherited Retinal Disease Market Segments Analysis
Global inherited retinal disease market is segmented by disease type, therapy type, route of administration, end user, distribution channel and region. Based on disease type, the market is segmented into retinitis pigmentosa (RP), leber congenital amaurosis (LCA), stargardt disease, choroideremia, cone-rod dystrophy (CRD), achromatopsia, X-linked retinoschisis (XLRS) and others. Based on therapy type, the market is segmented into gene therapy, cell therapy, pharmacological therapy, retinal prostheses (bionic vision) and supportive & symptomatic care. Based on route of administration, the market is segmented into intravitreal, subretinal, oral and others. Based on end user, the market is segmented into hospitals, ophthalmology clinics, ambulatory surgical centers (ASCs) and research & academic institutes. Based on distribution channel, the market is segmented into hospital pharmacies, specialty pharmacies, retail pharmacies and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Inherited Retinal Disease Market
The Global Inherited Retinal Disease market is significantly driven by advancements in gene editing technologies, which enable the targeted correction of genetic mutations linked to hereditary retinal disorders. These innovative methods surpass traditional therapeutic approaches that primarily focused on addressing symptoms rather than the underlying genetic causes. The growing interest and investment in these cutting-edge treatments are expediting their development and validation in clinical settings. Furthermore, improved genetic engineering techniques enhance the accessibility and reliability of these treatments, fostering greater clinician confidence. Consequently, this progress translates into more effective clinical outcomes and expands the landscape of treatment opportunities for affected patients.
Restraints in the Global Inherited Retinal Disease Market
The Global Inherited Retinal Disease market faces significant restraints primarily due to the high costs associated with gene and cell-based therapies. This financial burden creates challenges for healthcare systems, particularly those operating with limited resources, as they struggle to access these advanced treatments. Reimbursement models complicate matters further, resulting in delays that restrict providers from offering comprehensive coverage, compelling patients to bear out-of-pocket expenses. Such delays hinder economic progress and limit market penetration, as many individuals await treatment. Additionally, the necessity for extensive long-term data in cost-effectiveness studies exacerbates pricing negotiations, while insufficient funding within the biotech sector reduces the number of viable treatment candidates, leading to unpredictable market dynamics.
Market Trends of the Global Inherited Retinal Disease Market
The Global Inherited Retinal Disease market is witnessing a transformative market trend driven by the expansion of gene therapy pipelines. Innovative advancements in vector design, alongside enhanced delivery mechanisms and safety protocols, are enabling the development of therapies for a broader range of previously underserved inherited retinal disorders. Increased collaboration among research institutions and improvements in regulatory frameworks are streamlining the transition from preclinical research to clinical trials. This acceleration is attracting significant investor interest and fostering strategic partnerships, further enriching the landscape of treatment options and propelling the market forward, thus offering hope for addressing rare retinal diseases effectively.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Inherited Retinal Disease Market Size by Disease Type & CAGR (2026-2033)
- Market Overview
- Retinitis Pigmentosa (RP)
- Leber Congenital Amaurosis (LCA)
- Stargardt Disease
- Choroideremia
- Cone-Rod Dystrophy (CRD)
- Achromatopsia
- X-Linked Retinoschisis (XLRS)
- Others
Global Inherited Retinal Disease Market Size by Therapy Type & CAGR (2026-2033)
- Market Overview
- Gene Therapy
- Cell Therapy
- Pharmacological Therapy
- Retinal Prostheses (Bionic Vision)
- Supportive & Symptomatic Care
Global Inherited Retinal Disease Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Intravitreal
- Subretinal
- Oral
- Others
Global Inherited Retinal Disease Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Ophthalmology Clinics
- Ambulatory Surgical Centers (ASCs)
- Research & Academic Institutes
Global Inherited Retinal Disease Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Specialty Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Inherited Retinal Disease Market Size & CAGR (2026-2033)
- North America (Disease Type, Therapy Type, Route of Administration, End User, Distribution Channel)
- US
- Canada
- Europe (Disease Type, Therapy Type, Route of Administration, End User, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Disease Type, Therapy Type, Route of Administration, End User, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Disease Type, Therapy Type, Route of Administration, End User, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Disease Type, Therapy Type, Route of Administration, End User, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genentech Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biogen Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sarepta Therapeutics Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- MeiraGTx Holdings plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Beacon Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- 4D Molecular Therapeutics Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Atsena Therapeutics Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Nanoscope Therapeutics Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Opus Genetics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Coave Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ProQR Therapeutics NV
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Jenssen Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson Services Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Regeneron Pharmaceuticals Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
